Workflow
Clinical-stage Life Sciences
icon
Search documents
Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025
Accessnewswire· 2025-10-15 21:00
Core Points - Revelation Biosciences, Inc. has adjourned its 2025 Special Meeting of Stockholders due to insufficient shares present for voting [1] - The Special Meeting was originally scheduled for October 15, 2025, and will now reconvene on October 29, 2025, at 12:00 p.m. [1] Company Summary - Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation [1]
Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds
Accessnewswire· 2025-09-11 12:30
Core Insights - Revelation Biosciences, Inc. has entered into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to 4,355,000 shares of common stock at an exercise price of $2.20 per share [1] Company Summary - The company is a clinical-stage life sciences firm focused on rebalancing inflammation [1] - The existing warrants were issued on May 29, 2025, and the shares are registered under an effective registration statement on Form S-1 [1]